Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a report issued on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Down 1.9 %

Shares of LPCN opened at $3.56 on Tuesday. The business has a 50-day simple moving average of $4.57 and a two-hundred day simple moving average of $4.64. The stock has a market cap of $19.05 million, a price-to-earnings ratio of -4.68 and a beta of 1.23. Lipocine has a 52 week low of $3.20 and a 52 week high of $11.79.

Institutional Trading of Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC raised its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.